Target intelligence / Profile preview

Amyloid-beta protein fibrils (Aβ fibrils)

Target
Aβ fibrils
Molecular classification
Other
01

Overview

Amyloid-beta (Aβ) fibrils and insoluble plaque-associated Aβ represent the aggregated, beta-sheet-rich physical states of the amyloid-beta peptide, which is generated through the sequential proteolytic cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases. While monomeric Aβ is soluble and may have physiological roles, its misfolding and self-assembly into oligomers, protofibrils, and eventually mature insoluble fibrils lead to the formation of senile plaques in the brain parenchyma. These fibrillar aggregates and plaques are hallmark neuropathological features of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). They act as reservoirs of neurotoxicity, inducing synaptic dysfunction, neuroinflammation, oxidative stress, and downstream tau pathology, ultimately leading to neuronal death and cognitive decline.

Therapeutic strategies targeting these insoluble aggregates primarily utilize monoclonal antibodies designed to recognize specific conformational epitopes of aggregated Aβ. Upon binding, these antibodies facilitate the clearance of plaques and fibrils through microglial-mediated phagocytosis. Clinical trials of anti-Aβ antibodies, such as lecanemab and donanemab, have demonstrated that substantial reduction of the amyloid plaque burden can modestly slow cognitive and functional decline in patients with early-stage Alzheimer's disease. However, targeting these insoluble structures is associated with significant safety concerns, most notably amyloid-related imaging abnormalities (ARIA) characterized by vasogenic edema or microhemorrhages, particularly in patients carrying the APOE ε4 allele.

Other names
Amyloid-beta fibrilsInsoluble plaque-associated AβAmyloid-beta peptide fibrilsAβ fibrilsAmyloid-beta plaquesFibrillar amyloid-betaAβ42 fibrilsAβ40 fibrils
02

Mechanism of action

Monoclonal antibodies bind to specific epitopes on amyloid-beta fibrils or plaque-associated aggregates, marking them for clearance via microglial-mediated phagocytosis. Other therapeutic approaches, such as small molecules or peptides, aim to inhibit fibril elongation, prevent aggregation, or promote the disassembly and dissociation of pre-formed fibrils into non-toxic monomeric species.

03

Biological functions

ApoptosisCell deathImmune responseOther
04

Disease associations

Neurodegenerative diseaseInflammation
05

Safety considerations

Amyloid-related imaging abnormalities with edema (ARIA-E)Amyloid-related imaging abnormalities with hemorrhage (ARIA-H)Brain swelling and microhemorrhagesIncreased risk of ARIA in APOE ε4 carriersInfusion-related reactionsLimited clinical efficacy relative to plaque clearanceDifficulty in crossing the blood-brain barrier
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Amyloid PET imagingCerebrospinal fluid Aβ42/Aβ40 ratioPlasma Aβ42/Aβ40 ratioCerebrospinal fluid phosphorylated tau (p-tau)Plasma phosphorylated tau (p-tau)Glial fibrillary acidic protein (GFAP)

Beyond the preview

Go deeper on Amyloid-beta protein fibrils (Aβ fibrils).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amyloid-beta protein fibrils (Aβ fibrils).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call